China-headquartered drug developer Adagene has raised $69 million in a Series D funding round led by US global growth equity firm General Atlantic, per a company statement.
While General Atlantic has infused $50 million, the remaining has been pumped by other investors such as Eight Roads Ventures China, F-Prime Capital, WuXi Corporate Venture Fund and Sequoia China.
